|
AU2026400A
|
|
Treatment of myelogenous leukemia
|
|
WO9942570A1
|
|
Cellular flip compositions for treatment of arteriosclerotic disorders
|
|
AU1698899A
|
|
N-acetylserotonin derivatives and uses thereof
|
|
EP1009441A1
|
|
Method for the treatment of grafts
|
|
AU6880498A
|
|
Method for treating depression, obsessive compulsive disorder or anxiety
|
|
AU6760298A
|
|
Method for treating hypertension
|
|
WO9810090A1
|
|
Gata-6 transcription factor: compositions and methods
|
|
US5858990A
|
|
Fas ligand compositions for treatment of proliferative disorders
|
|
US5980887A
|
|
Methods for enhancing angiogenesis with endothelial progenitor cells
|
|
US5652225A
|
|
Methods and products for nucleic acid delivery
|
|
WO9628093A1
|
|
Apparatus and process for reducing the frequency and duration of apneic events
|
|
US6121246A
|
|
Method for treating ischemic tissue
|
|
US5830879A
|
|
Treatment of vascular injury using vascular endothelial growth factor
|
